AnaptysBio, Inc. ANAB 深 滬
已收盤 08-01 16:00:00 美东时间
24.69
+0.140
+0.57%
華盛通- 最 高24.93
- 今 開24.44
- 成交量 32.69万股
- 最 低 24.00
- 昨 收 24.55
- 總市值 7.25亿
- 52周最高 41.3083
- 市盈率 靜 --
- 換手率 1.11%
- 52周最低 12.21
- 委 比 14.29%
- 總股本 2938.05万
- 歷史最高 134.00
- 量 比 0.66
- 振 幅 3.79%
- 歷史最低 10.00
- 每 手 1
- 風險率 7.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Analyst Expectations For AnaptysBio's Future
Across the recent three months, 5 analysts have shared their insights on Anapty...
07-25 02:00
JP Morgan Maintains Overweight on AnaptysBio, Raises Price Target to $80
JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $42 to $80.
07-24 22:13
华商绿能携手必维认证 推动绿色能源技术研究与标准建设
7月18日，华商能源旗下全资子公司华商绿能科技（深圳）有限公司（简称“华商绿能”）与必维认证（北京）有限公司（简称“必维认证”）在深圳正式签署战略合作协议。华商...
07-21 14:22
每天车闻：美国终止对日产汽车近六年的安全调查，杜超任小鹏汇天首席财务官
日前，美国国家公路交通安全管理局（NHTSA）的缺陷调查办公室（ODI）宣布，终止对日产汽车长达近六年的安全调查。此次调查涉及2013-2018款日产Alti...
06-23 22:49
美股大行评级 | 花旗首予霸王茶姬"买入"评级，CrowdStrike、达乐公司、Guidewire Software、Snowflake获多家机构上调评级和目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137304602125590529.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Wolfe Research：维持Cheche Group(CCG)"跑赢大市"评级，目标价从335美元升至350美元</p> <p>• HC Wainwright & Co.：上调AnaptysBio(ANAB)
06-05 09:42
HC Wainwright & Co. Upgrades AnaptysBio to Buy, Raises Price Target to $38
HC Wainwright & Co. analyst Emily Bodnar upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Buy and raises the price target from $22 to $38.
06-04 19:16
Anaptys Reports Rosnilimab Data Updated Through Six Months In Phase 2b Trial In RA
Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment periodFavorable safety and tolerability, particularly when compared toBest-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment periodFavorable safety an
06-04 04:12
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
AnaptysBio announced positive results from a Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis (RA), demonstrating best-in-class efficacy comparable to JAK inhibitors with monthly dosing. The trial showed favorable safety and tolerability, with durable responses lasting at least two months off treatment. Rosnilimab achieved JAK-like efficacy in key measures, including low disease activity (LDA) and remission, with favorable...
06-03 20:05
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock
Across the recent three months, 5 analysts have shared their insights on Anapty...
05-29 04:00
